SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

被引：5

作者：

Nash, P. ^{[1
]}

Coates, L. C. ^{[2
]}

Kivitz, A. J. ^{[3
]}

Mease, P. J. ^{[4
,5
]}

Gladman, D. D. ^{[6
]}

Covarrubias-Cobos, J. A. ^{[7
]}

Fleishaker, D. ^{[8
]}

Wang, C. ^{[8
]}

Kudlacz, E. ^{[8
]}

Menon, S. ^{[8
]}

Hendrikx, T. ^{[9
]}

Kanik, K. S. ^{[8
]}

机构：

[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia

[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[3] Altoona Ctr Clin Res, Dept Rheumatol, Duncansville, PA USA

[4] Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Univ Toronto, Toronto Western Hosp, Dept Med, Toronto, ON, Canada

[7] Unidad Reumatol Las Amer SCP, Merida, Yucatan, Mexico

[8] Pfizer Inc, Groton, CT 06340 USA

[9] Pfizer Inc, Collegeville, PA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.1414

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0509

引用

页码：682 / 682

页数：1

共 50 条

[41] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
Cohen, Stanley
Pablos, Jose L.
Zhang, Nan
Rizzo, Warren
Muller, Gerhard
Padmanaban, Devi
Kivitz, Alan
Matsumoto, Alan K.
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[42] LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2)
Gladman, D. D.
Coates, L. C.
Van den Bosch, F.
Helliwell, P.
Tasset, C.
Meuleners, L.
Gilles, L.
Gheyle, L.
Trivedi, M.
Alani, M.
Besuyen, R.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 759 - 759
[43] Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis
Lloyd-Lavery, A.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 815 - 816
[44] Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Gladman, Dafna D.
Nash, Peter
Mease, Philip J.
Fitzgerald, Oliver
Duench, Stephanie
Cadatal, Mary Jane
Masri, Karim R.
ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
[45] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
Gladman, Dafna
Nash, Peter
Mease, Philip J.
FitzGerald, Oliver
Masri, Karim R.
Duench, Stephanie
Jane Cadatal, Mary
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801
[46] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
Lichtenstein, G. R.
Loftus, E. V., Jr.
Wei, S. C.
Damiao, A. O.
Judd, D.
Lawendy, N.
Chan, G.
Zhang, H.
Wang, W.
Thorpe, A. J.
Bloom, S.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
[47] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR: LONG-TERM EXTENSION STUDY OUTCOMES IN AN AUSTRALIAN RHEUMATOID ARTHRITIS POPULATION
Hall, S.
Nash, P.
Rischmueller, M.
Bossingham, D.
Cook, N.
Witcombe, D.
Kwok, K.
Thirunavukkarasu, K.
INTERNAL MEDICINE JOURNAL, 2014, 44 : 26 - 26
[48] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
Bloom, Stuart
Lichtenstein, Gary R.
Loftus, Edward V.
Lawendy, Nervin
Friedman, Gary S.
Zhang, Haiying
Wang, Wenjin
Thorpe, Andrew J.
Nduaka, Chudy I.
Su, Chinyu
GUT, 2018, 67 : A62 - A63
[49] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Jürgen Wollenhaupt
Eun-Bong Lee
Jeffrey R. Curtis
Joel Silverfield
Ketti Terry
Koshika Soma
Chris Mojcik
Ryan DeMasi
Sander Strengholt
Kenneth Kwok
Irina Lazariciu
Lisy Wang
Stanley Cohen
Arthritis Research & Therapy, 21
[50] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
Ruediger B. Mueller
Hendrik Schulze-Koops
Daniel E. Furst
Stanley B. Cohen
Kenneth Kwok
Lisy Wang
Tim Killeen
Johannes von Kempis
Clinical Rheumatology, 2022, 41 : 1045 - 1055

← 1 2 3 4 5 →